Kadmon Holdings, Inc.: Late-stage biotech developing small molecules and biologics; focused on inflammation, fibrosis and I-O. Lead candidate KD025 is a ROCK2 inhibitor in a registration trial cGVHD. Platform of ROCK inhibitors for fibrotic diseases. Also developing IL-15-contaning fusion proteins for I-O.
Website:
Address:
450 East 29th Street
New York, NY 10016
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.